Shenstone Biopharmaceutical

Shenstone Biopharmaceutical is a clinical-stage biotechnology company focused on the development of mRNA-based therapeutics and vaccines. Founded by experts with experience from leading global mRNA firms, the company utilizes a proprietary lipid nanoparticle (LNP) delivery platform to address unmet medical needs in infectious diseases, oncology, and rare genetic disorders. Shenstone's technology focuses on optimizing mRNA sequence design and LNP formulation to ensure high expression levels and safety. The company has successfully advanced several candidates into clinical trials, including a next-generation COVID-19 vaccine. Headquartered in Shenzhen, China, Shenstone has secured significant backing from prominent venture capital firms to expand its R&D and manufacturing capabilities.